What’s Going On With GameStop Stock Thursday?
GameStop's stock dropped 16% after CEO Ryan Cohen's plan to shift towards profitability and avoid meme-stock hype. The company also faces declining sales and criticism of its business model.
Kroger Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
The Kroger Co. (NYSE:KR) is set to release first quarter financial results, before the opening bell on Thursday.…
Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment
SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology,
Boeing 737 Max Crash Victim Families Call For $25B Fine As CEO Dave Calhoun Gets Grilled By Senators
The families' attorney, Paul Cassell, argues that the proposed fine is "legally justified and clearly appropriate."
Wall Street On Track To Resume Meteoric Climb, Nvidia Builds On Gains: Analyst Says ‘Now Until Later In The Month Is…Seasonally Worst Times’
U.S. stocks will likely carry over from where they left off as the market reopens after the Juneteenth holiday on Thursday. The major index futures were all uniformly higher, underpinned by the continued buoyancy in the tech space.
SAB Biotherapeutics Rebrands as SAB BIO, Focuses on Type 1 Diabetes Therapies
SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for
What’s Going On With Wolfspeed Stock Thursday?
Wolfspeed reportedly postpones $3B Germany plant to focus on NY production due to weak EV markets. Faces investor pressure after stock fell 51% in past year.
Altair Joins S&P MidCap 400, Marking Significant Growth Milestone
Altair (NASDAQ:ALTR), a global leader in computational intelligence, was added to the S&P MidCap 400 by S&P Dow Jones Indices effective prior to the open of trading on Monday, June
Neumora Initiates Phase 1b Trial for Alzheimer’s-Related Agitation Treatment
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a
Palantir Secures $19M ARPA-H Contract to Boost Health Outcomes with AI
Palantir Technologies Inc. (NYSE:PLTR) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to support the agency's mission to accelerate better health outcomes.